Trillium Therapeutics Inc (TRIL)

[NY1972]

Positive according to CMO. The billion $ question is if .2mg dose can wake up the macrophages to chew up tumors for breakfast.

Eric Sievers, MD. “Having established a well-tolerated dose and schedule of TTI-621, we are enthusiastic to characterize safety and anti-tumor activity across multiple blood cancers. In addition, we look forward to evaluating TTI-621 in combination with rituximab.”